⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28787512 | 0.73 | — | — | |
| SCHEMBL28553315 | 0.72 | — | — | |
| SCHEMBL18241872 | 0.72 | — | — | |
| SCHEMBL28944906 | 0.70 | — | — | |
| SCHEMBL6316778 | 0.70 | — | — | |
| SCHEMBL29133967 | 0.70 | — | — | |
| SCHEMBL6236880 | 0.69 | — | — | |
| SCHEMBL8569433 | 0.69 | — | — | |
| SCHEMBL8860014 | 0.69 | — | — | |
| SCHEMBL7695471 | 0.69 | CYP3A4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999063935-A2 | RAPID OPIOID DETOXIFICATION THERAPY AND ANTI-READDICTION THERAPY | U.S. DETOX, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| EP-0356128-B1 | 3-(AMINOPROPYL)METHYL PHOSPHINIC ACID AS A THERAPEUTIC AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-07-01 | — | — | EP | claimed |
| WO-1990001936-A1 | 3-(AMINOPROPYL)METHYL PHOSPHINIC ACID AS A THERAPEUTIC AGENT AND INTERMEDIATES IN ITS SYNTHESIS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-08 | — | — | WO | claimed |
| EP-0356128-A2 | 3-(Aminopropyl)methyl phosphinic acid as a therapeutic agent | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-28 | — | — | EP | claimed |
| US-11872200-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | disclosed |
| US-10952980-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3753410-A2 | COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-2621282-B1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | UNIV CALIFORNIA (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200030272-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-30 | — | — | US | disclosed |
| US-10434078-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180193295-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-12 | — | — | US | disclosed |
| EP-0506853-A1 | THE USE OF GABA-B SELECTIVE AGONISTS AS ANTI-TUSSIVE AGENTS. | SCHERING CORP (US) | 1992-10-07 | — | — | EP | disclosed |
| EP-0356128-B1 | 3-(AMINOPROPYL)METHYL PHOSPHINIC ACID AS A THERAPEUTIC AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-07-01 | — | — | EP | disclosed |
| WO-1991008740-A1 | THE USE OF GABA-B SELECTIVE AGONISTS AS ANTI-TUSSIVE AGENTS | SCHERING CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| WO-1990001936-A1 | 3-(AMINOPROPYL)METHYL PHOSPHINIC ACID AS A THERAPEUTIC AGENT AND INTERMEDIATES IN ITS SYNTHESIS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-08 | — | — | WO | disclosed |
| WO-1990001936-A1 | 3-(AMINOPROPYL)METHYL PHOSPHINIC ACID AS A THERAPEUTIC AGENT AND INTERMEDIATES IN ITS SYNTHESIS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-08 | — | — | WO | disclosed |
| EP-0356128-A2 | 3-(Aminopropyl)methyl phosphinic acid as a therapeutic agent | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-28 | — | — | EP | disclosed |
| EP-0356128-A2 | 3-(Aminopropyl)methyl phosphinic acid as a therapeutic agent | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-28 | — | — | EP | disclosed |
| EP-0356128-A2 | 3-(Aminopropyl)methyl phosphinic acid as a therapeutic agent | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-28 | — | — | EP | disclosed |